Achondroplasia Clinical Trials and Treatments

Achondroplasia is caused by a gain-of-function mutation in the FGFR3 gene on chromosome 4, which encodes a receptor that normally limits bone growth. Nearly all cases (over 97%) involve the same specific mutation (G380R), making it one of the most genetically uniform rare diseases. The overactive FGFR3 receptor suppresses growth plate activity in the long bones, leading to shortened limbs while the trunk grows to near-normal size.

The most common symptoms of Achondroplasia include Short stature with disproportionately short arms and legs, especially upper arms and thighs, Large head (macrocephaly) with prominent forehead and flattened nasal bridge, Limited elbow extension and reduced range of motion at multiple joints, Bowed legs (genu varum) that worsen with walking, Exaggerated lower back curve (lumbar lordosis) with prominent abdomen, among others. Approximately 1 in 25,000 live births; estimated 25,000 to 30,000 people in the United States. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Achondroplasia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Clinical trials for achondroplasia are exploring multiple strategies to promote bone growth and address the complications of FGFR3 overactivation. Voxzogo (vosoritide), a daily injection approved in November 2021, established the path for growth-promoting therapies, and in February 2026 the FDA approved Yuviwel (navepegritide), a once-weekly CNP injection for children 2 and older whose growth plates are still open.

Yes. As of October 14, 2026, 2 FDA-approved medicines have a current label that names Achondroplasia: Yuviwel (navepegritide), first approved in 2026; and Voxzogo (vosoritide). Corticosteroids and immune globulins count once each. The FDA is due to decide on Infigratinib by February 4, 2027 and Voxzogo (vosoritide) by February 28, 2027; the FDA calendar page carries the outcome the day it lands.

Achondroplasia is caused by variants in the FGFR3 gene. Two specific FGFR3 variants (almost always p.Gly380Arg) account for nearly all cases; about 80% are de novo.

It is autosomal dominant, so each child of an affected parent has a 1 in 2 chance of inheriting it. Approximately 1 in 25,000 live births; estimated 25,000 to 30,000 people in the United States. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Achondroplasia looks at the FGFR3 gene. Two specific FGFR3 variants (almost always p.Gly380Arg) account for nearly all cases; about 80% are de novo.

It is autosomal dominant, so each child of an affected parent has a 1 in 2 chance of inheriting it.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Achondroplasia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Achondroplasia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.